A Single-Center, Cross-Sectional Study of PET-MRI with (11)C-UCB-J (synaptic vesicle protein 2A), (18)F-MK-6240 (tau deposition), and (11)C-Pittsburgh compound B (β-amyloid) and neuropsychological assessment
Latest Information Update: 17 Jun 2020
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Amnesia; Mild cognitive impairment
- Focus Diagnostic use; Pharmacodynamics
Most Recent Events
- 17 Jun 2020 New trial record
- 03 Jun 2020 Results published in the Neurology Journal.